September 18, 2019
FDA gives Breakthrough Therapy Designation for Genentech’s Gazyva in Lupus Nephritis
Lupus Nephritis
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Genentech
September 13, 2019
Genentech Presents New Six-year Ocrevus (Ocrelizumab) Data Which Showed That Earlier Initiation and Continuation of Treatment Reduced Disability Progression in Multiple Sclerosis
– Post-hoc analysis from a Phase III open-label extension study showed a 42% reduction in the risk of PPMS patients…
September 13, 2019
Genentech’s Fixed Dose Subcutaneous Combination of Perjeta and Herceptin Showed Non-Inferiority When Compared to Intravenous Formulations for People With HER2-Positive Breast Cancer
– New fixed-dose combination is administered under the skin in just minutes, significantly reducing the time spent receiving treatment –…
September 12, 2019
Genentech’s Satralizumab Significantly Reduced Relapse Risk in Second Positive Phase III Study for Neuromyelitis Optica Spectrum Disorder
– Pivotal Phase III SAkuraStar study shows 55% reduction in the risk of relapse for satralizumab monotherapy versus placebo presented…
September 12, 2019
Chugai Presents Results from Second Positive Global Phase III Clinical Study of Satralizumab in NMOSD at ECTRIMS 2019
Following a positive study where satralizumab was added to baseline therapy, satralizumab monotherapy significantly reduced risk of relapse by 55%…
September 10, 2019
Genentech’s Ocrevus data show NfL may be a biomarker for predicting future disability outcomes
– Blood neurofilament light chain (NfL) levels were significantly lowered following Ocrevus treatment in analyses of Phase III studies in…
August 5, 2019
Genentech’s Tecentriq combined with Platinum-based Chemotherapy Reduced the Risk of Disease Worsening or Death in People With Previously Untreated Advanced Bladder Cancer
– IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in previously untreated advanced bladder cancer…
July 3, 2019
Genentech Announces Positive Results for First Global Phase III Study Investigating One-dose XOFLUZA (Baloxavir Marboxil) in Children With the Flu
The MINISTONE-2 study showed XOFLUZA, given as a new oral suspension, is a well-tolerated and effective potential treatment for the flu in otherwise healthy children aged one to less than 12 years –
May 3, 2019
FDA Approves Genentech’s Kadcyla for Adjuvant Treatment HER2-Positive Early Breast Cancer
Approval based on data showing Kadcyla cut the risk of diseaserecurring by half compared to Herceptin in the adjuvant setting forspecific patients with HER2-positive early breast cancer
April 29, 2019
New Genentech Data at the 2019 AAN Annual Meeting Showcase Breadth and Promise of Neuroscience Portfolio
New data will be presented for risdiplam, an investigational oralsurvival motor neuron 2 (SMN2) splicing modifier for SMA, which isdesigned to increase and sustain SMN protein levels in the centralnervous system (CNS) and throughout the body.